

SHANKARLAL JAIN & ASSOCIATES LLP, CHARTERED ACCOUNTANTS
Address: 12, Engineer Building, 265 Princess Street, Mumbai – 400 002, India

To,
The Board of Directors,
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Mumbai

Dear Sir,

Re: **Limited Review of Un-audited Financial Results for the Half Year ended 30th September, 2017 in respect of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)**

Introduction

We have reviewed the accompanying statement of unaudited financial results of **M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)** for the half year ended **30th September, 2017**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a Report on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review of Interim Financial Information performed issued by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS**

Firm Registration No. 109901W/W100082

Sd/-

SATISH JAIN

**PARTNER
M. No. 048874**

Place : MUMBAI

Dated : 30/10/17

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

STANDALONE BALANCE SHEET AS AT 30 Sept 2017

Particulars	(Amount in INR)	(Amount in INR)
	As at 30 Sept 2017 Amount (Unaudited)	As at 31 March 2017 Amount (Audited)
I. EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	100,000	100,000
(b) Reserves and surplus	(2,376,553)	(2,214,980)
2 Non-current liabilities		
(a) Long-term borrowings	250,000,000	250,000,000
(b) Deferred tax liabilities	-	-
(c) Other Long term liabilities	-	-
(d) Long-term provisions	-	-
3 Current liabilities		
(a) Short-term borrowings	-	-
(b) Trade payables	-	-
(c) Other current liabilities	1,365,698	1,817,241
(d) Short-term provisions	443,830	408,830
TOTAL	249,532,975	250,111,091
II. ASSETS		
1 Non-current assets		
(a) Fixed assets		
(i) Tangible assets	-	-
(ii) Intangible assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible assets under development	-	-
(b) Non-current investments	248,995,479	248,995,479
(c) Long-term loans and advances	-	-
2 Current assets		
(a) Inventories	-	-
(b) Trade receivables	-	-
(c) Cash and cash equivalents	459,438	1,115,612
(d) Short-term loans and advances	-	-
(e) Other current assets	78,058	-
TOTAL	249,532,975	250,111,091

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

For Genlink Pharma Solutions Private limited

For Shankarlal Jain & Associates LLP
Chartered Accountants
Registration No : 109901W/W100082
Sd/-

Satish Jain
Partner
Membership No. : 048874
Mumbai
Date : 30/10/2017

Sd/-

Anand Shah

Director

DIN: - 00597145

Navi Mumbai

Date: 30/10/2017

Sd/-

Susheel Koul

Managing Director

DIN: - 00925887

Navi Mumbai

Sd/-

Somnath Bomble

Chief Financial Officer

Navi Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDING 30 Sep 2017

Particulars	(Amount in INR)	(Amount in INR)
	For the Half year ended 30 Sept 2017	For the year ended 31 March 2017
	Amount (Unaudited)	Amount (Audited)
I REVENUE		
Revenue from operations	-	1,750,000
Other income	-	-
Total Revenue	-	1,750,000
II EXPENSES		
Cost of materials consumed	-	-
Purchases of Stock-in-Trade	-	-
Changes in inventories of finished goods , WIP and Stock-in-Trade	-	-
Employee benefit expenses	-	-
Finance costs	3,889	1,538,265
Depreciation and amortisation expenses	-	-
Other expenses	157,683	1,894,885
Total expenses	161,572	3,433,150
III Profit/(Loss) before tax (I-II)	(161,572)	(1,683,150)
IV Tax expense		
Current tax	-	531,830
Deferred tax (Assets)/Liability	-	-
(Excess)/Short Provision for Tax	-	-
V Profit/(Loss) after tax (III-IV)	(161,572)	(2,214,980)
VI Earnings Per Share		
-Basic & Diluted	(16.16)	(244.99)

For Genlink Pharma Solutions Private limited

For Shankarlal Jain & Associates LLP
Chartered Accountants
Registration No : 109901W/W100082
Sd/-

Satish Jain
Partner
Membership No. : 048874
Mumbai
Date : 30/10/2017

Sd/-

Anand Shah
Director
DIN: - 00597145
Navi Mumbai
Date: 30/10/2017

Sd/-

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai

Sd/-

Somnath Bomble
Chief Financial Officer
Navi Mumbai